Breadcrumb

Breadcrumbs

PAGE UNDER CONSTRUCTION

PAGE UNDER CONSTRUCTION

PAGE UNDER CONSTRUCTION

ADC Franchise More Stories Content

More Stories

ADC Franchise

The investigational Antibody Drug Conjugate (ADC) Franchise of the Daiichi Sankyo Cancer Enterprise is built around our proprietary DXd ADC technology, which is being researched across multiple types of cancer. Our proprietary linker and payload technologies have been specifically designed to potentially address various limitations of two critical components of an ADC: the payload and linker

read more ...